Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIGERR-HL: Tislelizumab Plus Gemcitabine and Cisplatin in R/R Hodgkin Lymphoma
NCT05502250Phase 2Active, not recruiting
- Sponsor
- HOVON
- Start
- Jul 2023
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in Hodgkin lymphoma (HL), sponsored by HOVON. Primary endpoint: Progression Free Survival Probability at 2 Years. Started Jul 2023; status: active, not recruiting.
02
Drugs
tislelizumab
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT05502250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05502250.